Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Dean F. Bajorin, Andrea Necchi et al.|New England Journal of Medicine|2017Cited by 3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Intermittent versus Continuous Androgen Deprivation in Prostate CancerMaha Hussain, Ian M. Thompson, Catherine M. Tangen et al.|New England Journal of Medicine|2013Cited by 568
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upYves Fradet, Dean F. Bajorin, Joaquim Bellmunt et al.|Annals of Oncology|2019Cited by 484
Appropriate Use Criteria for <sup>18</sup>F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant DiseaseHossein Jadvar, Landis K. Griffeth, Patrick M. Colletti et al.|Journal of Nuclear Medicine|2017Cited by 99